HUMULIN N (insulin human) by Eli Lilly and Company. Approved for insulin [epc]. First approved in 1982.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
HUMULIN N is a human insulin (NPH) injection approved by the FDA in 1982 for the treatment of diabetes mellitus. It works by regulating glucose metabolism through stimulation of peripheral glucose uptake in skeletal muscle and fat, while inhibiting hepatic glucose production. The product also inhibits lipolysis and proteolysis while enhancing protein synthesis. As a long-acting basal insulin, HUMULIN N represents a foundational therapy in diabetes management, particularly for patients requiring intermediate-acting insulin coverage.
Insulin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.
Worked on HUMULIN N at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Data not available. Zero linked job openings are currently associated with HUMULIN N, suggesting minimal active career development activity for this mature product. Historically, this product would have created roles for diabetes field specialists, endocrinology MSLs, and managed care account managers, with skills in insulin pharmacology, formulary advocacy, and patient education being most relevant.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo